Celldex Therapeutics

Feb 20, 2025 | onlinelibrary.wiley.com | Michael Murphy |Celldex Therapeutics |Laura Vitale |Thomas O'Neill

1 Introduction Biologic-based therapies targeting cytokine pathways have resulted in marked clinical benefit in many inflammatory and autoimmune disorders [1]. However, many of these diseases are heterogeneous in nature and are generally driven by a multitude of cell types, pathways, or mechanisms, which inherently limits the effectiveness of most therapies directed at single targets.